These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 12962951)

  • 21. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients.
    Takei M; Homma Y;
    Int J Urol; 2005 May; 12(5):456-64. PubMed ID: 15948744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
    Kelleher CJ; Reese PR; Pleil AM; Okano GJ
    Am J Manag Care; 2002 Dec; 8(19 Suppl):S608-15. PubMed ID: 12516955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new once-daily formulation of tolterodine provides superior efficacy and is well tolerated in women with overactive bladder.
    Swift S; Garely A; Dimpfl T; Payne C;
    Int Urogynecol J Pelvic Floor Dysfunct; 2003 Feb; 14(1):50-4; discussion 54-5. PubMed ID: 12601517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms.
    Rovner ES; Kreder K; Sussman DO; Kaplan SA; Carlsson M; Bavendam T; Guan Z
    J Urol; 2008 Sep; 180(3):1034-41. PubMed ID: 18639297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder.
    Jacquetin B; Wyndaele J
    Eur J Obstet Gynecol Reprod Biol; 2001 Sep; 98(1):97-102. PubMed ID: 11516807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlations among improvements in urgency urinary incontinence, health-related quality of life, and perception of bladder-related problems in incontinent subjects with overactive bladder treated with tolterodine or placebo.
    Van Kerrebroeck PE; Kelleher CJ; Coyne KS; Kopp Z; Brodsky M; Wang JT
    Health Qual Life Outcomes; 2009 Feb; 7():13. PubMed ID: 19226471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia.
    Rackley R; Weiss JP; Rovner ES; Wang JT; Guan Z;
    Urology; 2006 Apr; 67(4):731-6; discussion 736. PubMed ID: 16618562
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
    Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
    BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
    Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
    Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.
    Appell RA
    Urology; 1997 Dec; 50(6A Suppl):90-6; discussion 97-9. PubMed ID: 9426760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults.
    Garely AD; Burrows L
    Drug Saf; 2004; 27(13):1043-57. PubMed ID: 15471509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers.
    Chapple C; Herschorn S; Abrams P; Sun F; Brodsky M; Guan Z
    Eur Urol; 2009 Sep; 56(3):534-41. PubMed ID: 19070418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.
    Frenkl TL; Zhu H; Reiss T; Seltzer O; Rosenberg E; Green S
    J Urol; 2010 Aug; 184(2):616-22. PubMed ID: 20639026
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET).
    Sussman D; Garely A
    Curr Med Res Opin; 2002; 18(4):177-84. PubMed ID: 12201616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tolterodine once-daily in treatment of the overactive bladder.
    Peters KM; Huang RR
    Urology; 2001 Nov; 58(5):829-32. PubMed ID: 11711378
    [No Abstract]   [Full Text] [Related]  

  • 39. Onset of efficacy of tolterodine extended release in patients with overactive bladder.
    Sussman DO; Kraus SR; Carlsson M; Guan Z
    Curr Med Res Opin; 2007 Apr; 23(4):777-81. PubMed ID: 17407634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia.
    Nitti VW; Dmochowski R; Appell RA; Wang JT; Bavendam T; Guan Z;
    BJU Int; 2006 Jun; 97(6):1262-6. PubMed ID: 16686723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.